26
|
Morison JK, Homann J, Hammett MV, Lister N, Layton D, Malin MA, Thorburn AN, Chidgey AP, Boyd RL, Heng TSP. Establishment of transplantation tolerance via minimal conditioning in aged recipients. Am J Transplant 2014; 14:2478-90. [PMID: 25220786 DOI: 10.1111/ajt.12929] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2013] [Revised: 07/07/2014] [Accepted: 07/10/2014] [Indexed: 01/25/2023]
Abstract
Mixed hematopoietic chimerism is a powerful means of generating donor-specific tolerance, allowing long-term graft acceptance without lifelong dependence on immunosuppressive drugs. To avoid the need for whole body irradiation and associated side effects, we utilized a radiation-free minimal conditioning regime to induce long-term tolerance across major histocompatibility barriers. We found that low-dose busulfan, in combination with host T cell depletion and short-term sirolimus-based immunosuppression, facilitated efficient donor engraftment. Tolerance was achieved when mice were transplanted with whole or T cell-depleted bone marrow, or purified progenitor cells. Tolerance induction was associated with an expansion in regulatory T cells and was not abrogated in the absence of a thymus, suggesting a dominant or compensatory peripheral mode of tolerance. Importantly, we were able to generate durable chimerism and tolerance to donor skin grafts in both young and aged mice, despite age-related thymic atrophy and immune senescence. Clinically, this is especially relevant as the majority of transplant recipients are older patients whose immune recovery might be dangerously slow and would benefit from radiation-free minimal conditioning regimes that allow efficient donor engraftment without fully ablating the recipient immune system.
Collapse
|
27
|
Adare A, Afanasiev S, Aidala C, Ajitanand N, Akiba Y, Al-Bataineh H, Alexander J, Angerami A, Aoki K, Apadula N, Aphecetche L, Aramaki Y, Asai J, Atomssa E, Averbeck R, Awes T, Azmoun B, Babintsev V, Bai M, Baksay G, Baksay L, Baldisseri A, Barish K, Barnes P, Bassalleck B, Basye A, Bathe S, Batsouli S, Baublis V, Baumann C, Bazilevsky A, Belikov S, Belmont R, Bennett R, Berdnikov A, Berdnikov Y, Bhom J, Bickley A, Blau D, Boissevain J, Bok J, Borel H, Boyle K, Brooks M, Buesching H, Bumazhnov V, Bunce G, Butsyk S, Camacho C, Campbell S, Caringi A, Chang B, Chang W, Charvet JL, Chen CH, Chernichenko S, Chi C, Chiu M, Choi I, Choi J, Choudhury R, Christiansen P, Chujo T, Chung P, Churyn A, Chvala O, Cianciolo V, Citron Z, Cole B, Conesa del Valle Z, Connors M, Constantin P, Csanád M, Csörgő T, Dahms T, Dairaku S, Danchev I, Das K, Datta A, David G, Dayananda M, Denisov A, d’Enterria D, Deshpande A, Desmond E, Dharmawardane K, Dietzsch O, Dion A, Donadelli M, Drapier O, Drees A, Drees K, Dubey A, Durham J, Durum A, Dutta D, Dzhordzhadze V, D’Orazio L, Edwards S, Efremenko Y, Ellinghaus F, Engelmore T, Enokizono A, En’yo H, Esumi S, Eyser K, Fadem B, Feege N, Fields D, Finger M, Finger M, Fleuret F, Fokin S, Fraenkel Z, Frantz J, Franz A, Frawley A, Fujiwara K, Fukao Y, Fusayasu T, Garishvili I, Glenn A, Gong H, Gonin M, Gosset J, Goto Y, Granier de Cassagnac R, Grau N, Greene S, Grim G, Grosse Perdekamp M, Gunji T, Gustafsson HÅ, Hadj Henni A, Haggerty J, Hahn K, Hamagaki H, Hamblen J, Han R, Hanks J, Hartouni E, Haruna K, Haslum E, Hayano R, He X, Heffner M, Hemmick T, Hester T, Hill J, Hohlmann M, Holzmann W, Homma K, Hong B, Horaguchi T, Hornback D, Huang S, Ichihara T, Ichimiya R, Iinuma H, Ikeda Y, Imai K, Imrek J, Inaba M, Isenhower D, Ishihara M, Isobe T, Issah M, Isupov A, Ivanischev D, Iwanaga Y, Jacak B, Jia J, Jiang X, Jin J, Johnson B, Jones T, Joo K, Jouan D, Jumper D, Kajihara F, Kametani S, Kamihara N, Kamin J, Kang J, Kapustinsky J, Karatsu K, Kasai M, Kawall D, Kawashima M, Kazantsev A, Kempel T, Khanzadeev A, Kijima K, Kikuchi J, Kim A, Kim B, Kim D, Kim D, Kim E, Kim EJ, Kim S, Kim YJ, Kinney E, Kiriluk K, Kiss Á, Kistenev E, Klay J, Klein-Boesing C, Kleinjan D, Kochenda L, Komkov B, Konno M, Koster J, Kozlov A, Král A, Kravitz A, Kunde G, Kurita K, Kurosawa M, Kweon M, Kwon Y, Kyle G, Lacey R, Lai Y, Lajoie J, Layton D, Lebedev A, Lee D, Lee J, Lee K, Lee K, Lee T, Leitch M, Leite M, Lenzi B, Li X, Lichtenwalner P, Liebing P, Linden Levy L, Liška T, Litvinenko A, Liu H, Liu M, Love B, Lynch D, Maguire C, Makdisi Y, Malakhov A, Malik M, Manko V, Mannel E, Mao Y, Mašek L, Masui H, Matathias F, McCumber M, McGaughey P, McGlinchey D, Means N, Meredith B, Miake Y, Mibe T, Mignerey A, Mikeš P, Miki K, Milov A, Mishra M, Mitchell J, Mohanty A, Moon H, Morino Y, Morreale A, Morrison D, Moukhanova T, Mukhopadhyay D, Murakami T, Murata J, Nagamiya S, Nagle J, Naglis M, Nagy M, Nakagawa I, Nakamiya Y, Nakamura K, Nakamura T, Nakano K, Nam S, Newby J, Nguyen M, Nihashi M, Niida T, Nouicer R, Nyanin A, Oakley C, O’Brien E, Oda S, Ogilvie C, Oka M, Okada K, Onuki Y, Oskarsson A, Ouchida M, Ozawa K, Pak R, Palounek A, Pantuev V, Papavassiliou V, Park I, Park J, Park S, Park W, Pate S, Pei H, Peng JC, Pereira H, Peresedov V, Peressounko D, Petti R, Pinkenburg C, Pisani R, Proissl M, Purschke M, Purwar A, Qu H, Rak J, Rakotozafindrabe A, Ravinovich I, Read K, Rembeczki S, Reygers K, Riabov V, Riabov Y, Richardson E, Roach D, Roche G, Rolnick S, Rosati M, Rosen C, Rosendahl S, Rosnet P, Rukoyatkin P, Ružička P, Rykov V, Sahlmueller B, Saito N, Sakaguchi T, Sakai S, Sakashita K, Samsonov V, Sano S, Sato T, Sawada S, Sedgwick K, Seele J, Seidl R, Semenov A, Semenov V, Seto R, Sharma D, Shein I, Shibata TA, Shigaki K, Shimomura M, Shoji K, Shukla P, Sickles A, Silva C, Silvermyr D, Silvestre C, Sim K, Singh B, Singh C, Singh V, Slunečka M, Soldatov A, Soltz R, Sondheim W, Sorensen S, Sourikova I, Staley F, Stankus P, Stenlund E, Stepanov M, Ster A, Stoll S, Sugitate T, Suire C, Sukhanov A, Sziklai J, Takagui E, Taketani A, Tanabe R, Tanaka Y, Taneja S, Tanida K, Tannenbaum M, Tarafdar S, Taranenko A, Tarján P, Themann H, Thomas D, Thomas T, Togawa M, Toia A, Tomášek L, Tomita Y, Torii H, Towell R, Tram VN, Tserruya I, Tsuchimoto Y, Vale C, Valle H, van Hecke H, Vazquez-Zambrano E, Veicht A, Velkovska J, Vértesi R, Vinogradov A, Virius M, Vossen A, Vrba V, Vznuzdaev E, Wang X, Watanabe D, Watanabe K, Watanabe Y, Wei F, Wei R, Wessels J, White S, Winter D, Woody C, Wright R, Wysocki M, Xie W, Yamaguchi Y, Yamaura K, Yang R, Yanovich A, Ying J, Yokkaichi S, You Z, Young G, Younus I, Yushmanov I, Zajc W, Zaudtke O, Zhang C, Zhou S, Zolin L. Measurement of transverse-single-spin asymmetries for midrapidity and forward-rapidity production of hadrons in polarizedp+pcollisions ats=200and 62.4 GeV. Int J Clin Exp Med 2014. [DOI: 10.1103/physrevd.90.012006] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
28
|
Osborne V, Layton D, Shakir SA. Implications of off-label use: An example from the final results of an observational cohort study on Intrinsa® (testosterone patch). Post Reprod Health 2014; 20:48-54. [PMID: 24879745 DOI: 10.1177/2053369114535762] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
INTRODUCTION Off-label use is where a medicinal product is used for a medical purpose not in accordance with the authorised product information. Intrinsa® is a transdermal testosterone patch, which is indicated for use in hypoactive sexual desire disorder in bilaterally oophorectomised and hysterectomised women receiving concomitant estrogen therapy. OBJECTIVES To describe the utilization characteristics of patients prescribed testosterone patch (Intrinsa®) and to assess, where possible, if the product is being used according to the authorised product information. STUDY DESIGN Patients identified from dispensed prescriptions issued by general practitioners for Intrinsa® between March 2007 and August 2010. Postal questionnaires were sent to general practitioners six months following the date of the first prescription for Intrinsa® for each patient, requesting information including patient demographics and drug utilization. MAIN OUTCOME MEASURES Menopausal status and use of concomitant estrogen therapy. RESULTS The final cohort consisted of 3073 patients; the majority were females (3017, 98.2%). The most commonly reported indication was hypoactive sexual desire disorder in 2324 female patients (77.0%). Only 43.5% female patients (n = 1313) were reported to have been hysterectomised and bilaterally oophorectomised. For 1029 (34.1%) female patients there was no evidence that the patient was using concomitant estrogen therapy. Overall, only 643 patients (20.9%) in the cohort were being prescribed Intrinsa® according to the manufacturer's recommendations. CONCLUSIONS Evidence obtained solely from clinical trials might not be generalisable where off-label prescribing occurs in real-life, so evidence from post-marketing observational studies is important to provide complimentary data on a product's safety and effectiveness.
Collapse
|
29
|
Layton D, Peck CC, Whittle T, Klineberg IJ. A clinical trial of active and passive treatment for TMD: a pilot study. Aust Dent J 2014. [DOI: 10.1111/j.1834-7819.2007.tb06131.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
30
|
Buggy Y, Cornelius V, Fogg C, Kasliwal R, Layton D, Shakir SAW. Neuropsychiatric events with varenicline: a modified prescription-event monitoring study in general practice in England. Drug Saf 2014; 36:521-31. [PMID: 23657823 DOI: 10.1007/s40264-013-0046-6] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
BACKGROUND Varenicline (Champix(®)), launched in the UK in December 2006, is indicated for the treatment of smoking cessation in adults (≥18 years of age). In 2008, the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK issued a warning suggesting that varenicline was associated with disparate neuropsychiatric symptoms, including depression, suicidal thoughts and behaviour. In response to this regulatory warning, the Drug Safety Research Unit conducted a modified prescription-event monitoring (M-PEM) study to monitor the safety of varenicline. OBJECTIVE The aim of this study was to estimate the incidence and examine the pattern of neuropsychiatric events reported to general practitioners (GPs) in England during the immediate postmarketing period for varenicline. METHODS A postmarketing surveillance study was conducted using the observational cohort technique of M-PEM. Patients were identified from dispensed prescriptions issued by primary care physicians between December 2006 and March 2007. Data on exposure, previous history of psychiatric illness and events reported during and after treatment were collected from questionnaires. In order to determine whether hazards for neuropsychiatric events of interest (depression, anxiety, aggression, suicidal ideation, non-fatal self-harm) were non-constant over time (which could indicate a possible association with the drug), the pattern of events was examined by plotting the smoothed hazard function estimate and then fitting a Weibull model. The Weibull model shape parameter (β) and 95 % confidence interval were used as a test for a non-constant hazard function (where a value of 1 indicates a constant hazard over time). In addition to this analysis, the difference in incidence densities (IDs) between month 1 and months 2-3 were calculated and compared. RESULTS The cohort comprised of 12,159 patients (median age 47 years [interquartile range 19]; 56.9 % [n = 6924 female]). The number of events reported during treatment, reason for stopping, adverse drug reactions (ADRs), and the p-value for the Weibull shape parameter were as follows: depression (n = 94; 42; 19; p = 0.144); anxiety (n = 94; 49; 9; p = 0.009); aggression (n = 7; 4; 2; p = 0.465); suicidal ideation (n = 8; 4; 1; p = 0.989) and non-fatal self-harm (n = 5; 1; 0; p = 0.771). No differences in the IDs between months 1 and months 2-3 were found for any of the events. CONCLUSION Whilst between 7 and 17 % of neuropsychiatric events were attributed to the drug by GPs and approximately 20-50 % were given as reasons for stopping, no signal was raised using the ID differences approach, and only anxiety was flagged as a potential signal for an ADR using the Weibull model. The signal for anxiety requires further evaluation to determine whether the drug plays a part in the development of anxiety or whether it is a withdrawal symptom caused by smoking cessation. Analysis methods will lack power when the numbers of events are low even when a large number of participants are included in the study.
Collapse
|
31
|
Osborne V, Layton D, Fogg C, Al-Shukri M, Shakir S. Utilization of fentanyl buccal tablets in England: Exploring off-label use reported in a cohort study. Eur J Pain 2013; 18:506-12. [DOI: 10.1002/j.1532-2149.2013.00389.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/22/2013] [Indexed: 11/10/2022]
|
32
|
Adare A, Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Akimoto R, Al-Bataineh H, Al-Ta'ani H, Alexander J, Angerami A, Aoki K, Apadula N, Aphecetche L, Aramaki Y, Armendariz R, Aronson SH, Asai J, Asano H, Aschenauer EC, Atomssa ET, Averbeck R, Awes TC, Azmoun B, Babintsev V, Bai M, Baksay G, Baksay L, Baldisseri A, Bannier B, Barish KN, Barnes PD, Bassalleck B, Basye AT, Bathe S, Batsouli S, Baublis V, Baumann C, Baumgart S, Bazilevsky A, Belikov S, Belmont R, Bennett R, Berdnikov A, Berdnikov Y, Bickley AA, Bing X, Blau DS, Boissevain JG, Bok JS, Borel H, Boyle K, Brooks ML, Buesching H, Bumazhnov V, Bunce G, Butsyk S, Camacho CM, Campbell S, Castera P, Chang BS, Chang WC, Charvet JL, Chen CH, Chernichenko S, Chi CY, Chiba J, Chiu M, Choi IJ, Choi JB, Choi S, Choudhury RK, Christiansen P, Chujo T, Chung P, Churyn A, Chvala O, Cianciolo V, Citron Z, Cleven CR, Cole BA, Comets MP, Connors M, Constantin P, Csanád M, Csörgő T, Dahms T, Dairaku S, Danchev I, Das K, Datta A, Daugherity MS, David G, Deaton MB, Dehmelt K, Delagrange H, Denisov A, d'Enterria D, Deshpande A, Desmond EJ, Dharmawardane KV, Dietzsch O, Ding L, Dion A, Donadelli M, Drapier O, Drees A, Drees KA, Dubey AK, Durham JM, Durum A, Dutta D, Dzhordzhadze V, D'Orazio L, Edwards S, Efremenko YV, Egdemir J, Ellinghaus F, Emam WS, Engelmore T, Enokizono A, En'yo H, Esumi S, Eyser KO, Fadem B, Fields DE, Finger M, Finger M, Fleuret F, Fokin SL, Fraenkel Z, Frantz JE, Franz A, Frawley AD, Fujiwara K, Fukao Y, Fusayasu T, Gadrat S, Gainey K, Gal C, Garishvili A, Garishvili I, Glenn A, Gong H, Gong X, Gonin M, Gosset J, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grosse Perdekamp M, Gunji T, Guo L, Gustafsson HÅ, Hachiya T, Hadj Henni A, Haegemann C, Haggerty JS, Hahn KI, Hamagaki H, Hamblen J, Han R, Hanks J, Harada H, Hartouni EP, Haruna K, Hashimoto K, Haslum E, Hayano R, He X, Heffner M, Hemmick TK, Hester T, Hiejima H, Hill JC, Hobbs R, Hohlmann M, Hollis RS, Holzmann W, Homma K, Hong B, Horaguchi T, Hori Y, Hornback D, Huang S, Ichihara T, Ichimiya R, Ide J, Iinuma H, Ikeda Y, Imai K, Imrek J, Inaba M, Inoue Y, Iordanova A, Isenhower D, Isenhower L, Ishihara M, Isobe T, Issah M, Isupov A, Ivanischev D, Jacak BV, Javani M, Jia J, Jiang X, Jin J, Jinnouchi O, Johnson BM, Joo KS, Jouan D, Jumper DS, Kajihara F, Kametani S, Kamihara N, Kamin J, Kaneta M, Kaneti S, Kang BH, Kang JH, Kang JS, Kanou H, Kapustinsky J, Karatsu K, Kasai M, Kawall D, Kawashima M, Kazantsev AV, Kempel T, Khanzadeev A, Kijima KM, Kikuchi J, Kim BI, Kim C, Kim DH, Kim DJ, Kim E, Kim EJ, Kim HJ, Kim KB, Kim SH, Kim YJ, Kim YK, Kinney E, Kiriluk K, Kiss Á, Kistenev E, Kiyomichi A, Klatsky J, Klay J, Klein-Boesing C, Kleinjan D, Kline P, Kochenda L, Kochetkov V, Komatsu Y, Komkov B, Konno M, Koster J, Kotchetkov D, Kotov D, Kozlov A, Král A, Kravitz A, Krizek F, Kubart J, Kunde GJ, Kurihara N, Kurita K, Kurosawa M, Kweon MJ, Kwon Y, Kyle GS, Lacey R, Lai YS, Lajoie JG, Layton D, Lebedev A, Lee B, Lee DM, Lee J, Lee K, Lee KB, Lee KS, Lee MK, Lee SH, Lee SR, Lee T, Leitch MJ, Leite MAL, Leitgab M, Leitner E, Lenzi B, Lewis B, Li X, Liebing P, Lim SH, Linden Levy LA, Liška T, Litvinenko A, Liu H, Liu MX, Love B, Luechtenborg R, Lynch D, Maguire CF, Makdisi YI, Makek M, Malakhov A, Malik MD, Manion A, Manko VI, Mannel E, Mao Y, Mašek L, Masui H, Masumoto S, Matathias F, McCumber M, McGaughey PL, McGlinchey D, McKinney C, Means N, Mendoza M, Meredith B, Miake Y, Mibe T, Mignerey AC, Mikeš P, Miki K, Miller TE, Milov A, Mioduszewski S, Mishra DK, Mishra M, Mitchell JT, Mitrovski M, Miyachi Y, Miyasaka S, Mohanty AK, Moon HJ, Morino Y, Morreale A, Morrison DP, Motschwiller S, Moukhanova TV, Mukhopadhyay D, Murakami T, Murata J, Nagae T, Nagamiya S, Nagata Y, Nagle JL, Naglis M, Nagy MI, Nakagawa I, Nakamiya Y, Nakamura KR, Nakamura T, Nakano K, Nattrass C, Nederlof A, Newby J, Nguyen M, Nihashi M, Niida T, Norman BE, Nouicer R, Novitzky N, Nyanin AS, O'Brien E, Oda SX, Ogilvie CA, Ohnishi H, Oka M, Okada K, Omiwade OO, Onuki Y, Oskarsson A, Ouchida M, Ozawa K, Pak R, Pal D, Palounek APT, Pantuev V, Papavassiliou V, Park BH, Park IH, Park J, Park SK, Park WJ, Pate SF, Patel L, Pei H, Peng JC, Pereira H, Peresedov V, Peressounko DY, Petti R, Pinkenburg C, Pisani RP, Proissl M, Purschke ML, Purwar AK, Qu H, Rak J, Rakotozafindrabe A, Ravinovich I, Read KF, Rembeczki S, Reuter M, Reygers K, Reynolds R, Riabov V, Riabov Y, Richardson E, Roach D, Roche G, Rolnick SD, Romana A, Rosati M, Rosen CA, Rosendahl SSE, Rosnet P, Rukoyatkin P, Ružička P, Rykov VL, Sahlmueller B, Saito N, Sakaguchi T, Sakai S, Sakashita K, Sakata H, Samsonov V, Sano M, Sano S, Sarsour M, Sato S, Sato T, Sawada S, Sedgwick K, Seele J, Seidl R, Semenov AY, Semenov V, Sen A, Seto R, Sharma D, Shein I, Shevel A, Shibata TA, Shigaki K, Shimomura M, Shoji K, Shukla P, Sickles A, Silva CL, Silvermyr D, Silvestre C, Sim KS, Singh BK, Singh CP, Singh V, Skutnik S, Slunečka M, Soldatov A, Soltz RA, Sondheim WE, Sorensen SP, Soumya M, Sourikova IV, Sparks NA, Staley F, Stankus PW, Stenlund E, Stepanov M, Ster A, Stoll SP, Sugitate T, Suire C, Sukhanov A, Sun J, Sziklai J, Tabaru T, Takagi S, Takagui EM, Takahara A, Taketani A, Tanabe R, Tanaka Y, Taneja S, Tanida K, Tannenbaum MJ, Tarafdar S, Taranenko A, Tarján P, Tennant E, Themann H, Thomas TL, Todoroki T, Togawa M, Toia A, Tojo J, Tomášek L, Tomášek M, Tomita Y, Torii H, Towell RS, Tram VN, Tserruya I, Tsuchimoto Y, Tsuji T, Vale C, Valle H, van Hecke HW, Vargyas M, Vazquez-Zambrano E, Veicht A, Velkovska J, Vértesi R, Vinogradov AA, Virius M, Vossen A, Vrba V, Vznuzdaev E, Wagner M, Walker D, Wang XR, Watanabe D, Watanabe K, Watanabe Y, Watanabe YS, Wei F, Wei R, Wessels J, White SN, Winter D, Wolin S, Wood JP, Woody CL, Wright RM, Wysocki M, Xie W, Yamaguchi YL, Yamaura K, Yang R, Yanovich A, Yasin Z, Ying J, Yokkaichi S, You Z, Young GR, Younus I, Yushmanov IE, Zajc WA, Zaudtke O, Zelenski A, Zhang C, Zhou S, Zimányi J, Zolin L. Medium modification of jet fragmentation in Au+Au collisions at √[s(NN)]=200 GeV measured in direct photon-hadron correlations. PHYSICAL REVIEW LETTERS 2013; 111:032301. [PMID: 23909311 DOI: 10.1103/physrevlett.111.032301] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/17/2012] [Indexed: 06/02/2023]
Abstract
The jet fragmentation function is measured with direct photon-hadron correlations in p+p and Au+Au collisions at √[s(NN)]=200 GeV. The p(T) of the photon is an excellent approximation to the initial p(T) of the jet and the ratio z(T)=p(T)(h)/p(T)(γ) is used as a proxy for the jet fragmentation function. A statistical subtraction is used to extract the direct photon-hadron yields in Au+Au collisions while a photon isolation cut is applied in p+p. I(AA), the ratio of hadron yield opposite the photon in Au+Au to that in p+p, indicates modification of the jet fragmentation function. Suppression, most likely due to energy loss in the medium, is seen at high z(T). The associated hadron yield at low z(T) is enhanced at large angles. Such a trend is expected from redistribution of the lost energy into increased production of low-momentum particles.
Collapse
|
33
|
Mackenzie IS, MacDonald TM, Shakir S, Dryburgh M, Mantay BJ, McDonnell P, Layton D. Influenza H1N1 (swine flu) vaccination: a safety surveillance feasibility study using self-reporting of serious adverse events and pregnancy outcomes. Br J Clin Pharmacol 2012; 73:801-11. [PMID: 22082196 PMCID: PMC3403208 DOI: 10.1111/j.1365-2125.2011.04142.x] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
AIMS During the global H1N1 influenza A (swine flu) pandemic 2009–2010, swine flu vaccines were expeditiously licensed and a mass vaccination programme for high risk groups, including pregnant women, was introduced in the UK. This pilot active safety surveillance study was performed to establish the feasibility of rapidly monitoring the new swine flu vaccines in large patient numbers receiving or offered the vaccination under normal conditions of use within a short time frame. METHODS A cohort design with safety data capture through modern technologies was carried out in Scotland, UK during the winter swine flu vaccination programme 2009–2010 in individuals receiving or offered the swine flu vaccination. The main outcome measures were self-reported serious adverse events (SAEs) and pregnancy outcomes. RESULTS The cohort comprised 4066 people; 3754 vaccinated and 312 offered the vaccination but not vaccinated. There were 939 self-reported events (838 different events), 53 judged to fit SAE criteria by the investigators, with nine judged as possibly, probably or definitely vaccine related. None of the seven deaths (six in vaccinees) were judged as vaccine related. One hundred and twenty-eight women reported 130 pregnancies during the study with 117 pregnant at study start. There were reports of four miscarriages in three women and six possible congenital abnormalities in live births. CONCLUSIONS Overall, no significant safety issues were identified. The methodology and use of modern technologies to collect safety data from large numbers of patients was successful and could be used again in similar safety studies.
Collapse
|
34
|
Layton D, Hazell L, Shakir SAW. Modified prescription-event monitoring studies: a tool for pharmacovigilance and risk management. Drug Saf 2012; 34:e1-9. [PMID: 22077508 DOI: 10.2165/11593830-000000000-00000] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Prescription-Event Monitoring (PEM) is a well established postmarketing surveillance technique designed to monitor the overall safety of newly marketed medicines as used in real-life clinical practice, usually in cohorts of at least 10 000 patients. At the Drug Safety Research Unit in the UK we are now moving towards a more targeted safety surveillance known as Modified PEM (M-PEM). These studies combine the advantages of conventional PEM studies (in monitoring general safety and identification of unexpected risks of a medicine) with that of a more targeted safety study that addresses specific questions (to better understand known or partially known risks with a medicine). Through the use of enhanced data collection questionnaires, M-PEM expands the range of applications of conventional PEM, which include more detailed characterization of real-life drug use, adherence to prescribing recommendations and targeted analysis of events requiring special monitoring by regulatory authorities. A particularly useful application is the evaluation of the safety of a medicine in special populations or subgroups (e.g. patients switching from another therapy or patients with a particular risk factor) or following important changes in the product's lifecycle (e.g. a licensing or formulation change). M-PEM studies therefore have an important contribution to make to pharmacovigilance and the risk management of medicines by providing valuable information on the use of new medications under real-life situations.
Collapse
|
35
|
Layton D, Osborne V, Gilchrist A, Shakir SAW. Examining the Utilization and Tolerability of the Non-Sedating Antihistamine Levocetirizine in England Using Prescription-Event Monitoring Data. Drug Saf 2011; 34:1177-89. [PMID: 22077506 DOI: 10.2165/11593930-000000000-00000] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
36
|
Adare A, Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Al-Bataineh H, Alexander J, Angerami A, Aoki K, Apadula N, Aphecetche L, Aramaki Y, Asai J, Atomssa ET, Averbeck R, Awes TC, Azmoun B, Babintsev V, Bai M, Baksay G, Baksay L, Baldisseri A, Barish KN, Barnes PD, Bassalleck B, Basye AT, Bathe S, Batsouli S, Baublis V, Baumann C, Bazilevsky A, Belikov S, Belmont R, Bennett R, Berdnikov A, Berdnikov Y, Bhom JH, Bickley AA, Blau DS, Boissevain JG, Bok JS, Borel H, Boyle K, Brooks ML, Buesching H, Bumazhnov V, Bunce G, Butsyk S, Camacho CM, Campbell S, Caringi A, Chang BS, Chang WC, Charvet JL, Chen CH, Chernichenko S, Chi CY, Chiu M, Choi IJ, Choi JB, Choudhury RK, Christiansen P, Chujo T, Chung P, Churyn A, Chvala O, Cianciolo V, Citron Z, Cole BA, Conesa del Valle Z, Connors M, Constantin P, Csanád M, Csörgo T, Dahms T, Dairaku S, Danchev I, Das K, Datta A, David G, Dayananda MK, Denisov A, d'Enterria D, Deshpande A, Desmond EJ, Dharmawardane KV, Dietzsch O, Dion A, Donadelli M, Drapier O, Drees A, Drees KA, Dubey AK, Durham JM, Durum A, Dutta D, Dzhordzhadze V, D'Orazio L, Edwards S, Efremenko YV, Ellinghaus F, Engelmore T, Enokizono A, En'yo H, Esumi S, Eyser KO, Fadem B, Fields DE, Finger M, Finger M, Fleuret F, Fokin SL, Fraenkel Z, Frantz JE, Franz A, Frawley AD, Fujiwara K, Fukao Y, Fusayasu T, Garishvili I, Glenn A, Gong H, Gonin M, Gosset J, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grim G, Grosse Perdekamp M, Gunji T, Gustafsson HÅ, Hadj Henni A, Haggerty JS, Hahn KI, Hamagaki H, Hamblen J, Han R, Hanks J, Hartouni EP, Haruna K, Haslum E, Hayano R, He X, Heffner M, Hemmick TK, Hester T, Hill JC, Hohlmann M, Holzmann W, Homma K, Hong B, Horaguchi T, Hornback D, Huang S, Ichihara T, Ichimiya R, Iinuma H, Ikeda Y, Imai K, Imrek J, Inaba M, Isenhower D, Ishihara M, Isobe T, Issah M, Isupov A, Ivanischev D, Iwanaga Y, Jacak BV, Jia J, Jiang X, Jin J, Johnson BM, Jones T, Joo KS, Jouan D, Jumper DS, Kajihara F, Kametani S, Kamihara N, Kamin J, Kang JH, Kapustinsky J, Karatsu K, Kasai M, Kawall D, Kawashima M, Kazantsev AV, Kempel T, Khanzadeev A, Kijima KM, Kikuchi J, Kim A, Kim BI, Kim DH, Kim DJ, Kim E, Kim EJ, Kim SH, Kim YJ, Kinney E, Kiriluk K, Kiss Á, Kistenev E, Klay J, Klein-Boesing C, Kochenda L, Komkov B, Konno M, Koster J, Kozlov A, Král A, Kravitz A, Kunde GJ, Kurita K, Kurosawa M, Kweon MJ, Kwon Y, Kyle GS, Lacey R, Lai YS, Lajoie JG, Layton D, Lebedev A, Lee DM, Lee J, Lee KB, Lee KS, Lee T, Leitch MJ, Leite MAL, Lenzi B, Li X, Lichtenwalner P, Liebing P, Linden Levy LA, Liška T, Litvinenko A, Liu H, Liu MX, Love B, Lynch D, Maguire CF, Makdisi YI, Malakhov A, Malik MD, Manko VI, Mannel E, Mao Y, Mašek L, Masui H, Matathias F, McCumber M, McGaughey PL, McGlinchey D, Means N, Meredith B, Miake Y, Mibe T, Mignerey AC, Mikeš P, Miki K, Milov A, Mishra M, Mitchell JT, Mohanty AK, Moon HJ, Morino Y, Morreale A, Morrison DP, Moukhanova TV, Mukhopadhyay D, Murakami T, Murata J, Nagamiya S, Nagle JL, Naglis M, Nagy MI, Nakagawa I, Nakamiya Y, Nakamura KR, Nakamura T, Nakano K, Nam S, Newby J, Nguyen M, Nihashi M, Niita T, Nouicer R, Nyanin AS, Oakley C, O'Brien E, Oda SX, Ogilvie CA, Oka M, Okada K, Onuki Y, Oskarsson A, Ouchida M, Ozawa K, Pak R, Palounek APT, Pantuev V, Papavassiliou V, Park IH, Park J, Park SK, Park WJ, Pate SF, Pei H, Peng JC, Pereira H, Peresedov V, Peressounko DY, Petti R, Pinkenburg C, Pisani RP, Proissl M, Purschke ML, Purwar AK, Qu H, Rak J, Rakotozafindrabe A, Ravinovich I, Read KF, Rembeczki S, Reygers K, Riabov V, Riabov Y, Richardson E, Roach D, Roche G, Rolnick SD, Rosati M, Rosen CA, Rosendahl SSE, Rosnet P, Rukoyatkin P, Ružička P, Rykov VL, Sahlmueller B, Saito N, Sakaguchi T, Sakai S, Sakashita K, Samsonov V, Sano S, Sato T, Sawada S, Sedgwick K, Seele J, Seidl R, Semenov AY, Semenov V, Seto R, Sharma D, Shein I, Shibata TA, Shigaki K, Shimomura M, Shoji K, Shukla P, Sickles A, Silva CL, Silvermyr D, Silvestre C, Sim KS, Singh BK, Singh CP, Singh V, Slunečka M, Soldatov A, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Staley F, Stankus PW, Stenlund E, Stepanov M, Ster A, Stoll SP, Sugitate T, Suire C, Sukhanov A, Sziklai J, Takagui EM, Taketani A, Tanabe R, Tanaka Y, Taneja S, Tanida K, Tannenbaum MJ, Tarafdar S, Taranenko A, Tarján P, Themann H, Thomas D, Thomas TL, Togawa M, Toia A, Tomášek L, Tomita Y, Torii H, Towell RS, Tram VN, Tserruya I, Tsuchimoto Y, Vale C, Valle H, van Hecke HW, Vazquez-Zambrano E, Veicht A, Velkovska J, Vértesi R, Vinogradov AA, Virius M, Vossen A, Vrba V, Vznuzdaev E, Wang XR, Watanabe D, Watanabe K, Watanabe Y, Wei F, Wei R, Wessels J, White SN, Winter D, Woody CL, Wright RM, Wysocki M, Xie W, Yamaguchi YL, Yamaura K, Yang R, Yanovich A, Ying J, Yokkaichi S, You Z, Young GR, Younus I, Yushmanov IE, Zajc WA, Zaudtke O, Zhang C, Zhou S, Zolin L. Cold nuclear matter effects on J/ψ yields as a function of rapidity and nuclear geometry in d+A collisions at sqrt[s(NN)]=200 GeV. PHYSICAL REVIEW LETTERS 2011; 107:142301. [PMID: 22107186 DOI: 10.1103/physrevlett.107.142301] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/07/2010] [Indexed: 05/31/2023]
Abstract
We present measurements of J/ψ yields in d+Au collisions at sqrt[s(NN)]=200 GeV recorded by the PHENIX experiment and compare them with yields in p+p collisions at the same energy per nucleon-nucleon collision. The measurements cover a large kinematic range in J/ψ rapidity (-2.2<y<2.4) with high statistical precision and are compared with two theoretical models: one with nuclear shadowing combined with final state breakup and one with coherent gluon saturation effects. In order to remove model dependent systematic uncertainties we also compare the data to a simple geometric model. The forward rapidity data are inconsistent with nuclear modifications that are linear or exponential in the density weighted longitudinal thickness, such as those from the final state breakup of the bound state.
Collapse
|
37
|
Heeley EL, Layton D, Shakir SA. Signal generation in prescription event monitoring: investigation of a possible signal of colitis during rofecoxib treatment. INTERNATIONAL JOURNAL OF PHARMACY PRACTICE 2011. [DOI: 10.1111/j.2042-7174.2002.tb00641.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Abstract
Focal points
Collapse
|
38
|
Layton D, Heeley E, Hughes K, Shakir SAW. Comparison of gastrointestinal events reported for rofecoxib and meloxicam using prescription-event monitoring data in England. INTERNATIONAL JOURNAL OF PHARMACY PRACTICE 2011. [DOI: 10.1111/j.2042-7174.2002.tb00653.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Abstract
Focal points
Collapse
|
39
|
Layton D, Riley J, Wilton L, Shakir SAW. Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring study. INTERNATIONAL JOURNAL OF PHARMACY PRACTICE 2011. [DOI: 10.1111/j.2042-7174.2002.tb00614.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Abstract
Focal points
Collapse
|
40
|
Lynn E, Layton D, Shakir S. New Postgraduate Qualifications in Pharmacovigilance from the Drug Safety Research Unit in the UK. Drug Saf 2011; 34:89-91. [DOI: 10.2165/11586810-000000000-00000] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
41
|
Osborne V, Layton D, Perrio M, Wilton L, Shakir SAW. Incidence of venous thromboembolism in users of strontium ranelate: an analysis of data from a prescription-event monitoring study in England. Drug Saf 2010; 33:579-91. [PMID: 20553059 DOI: 10.2165/11533770-000000000-00000] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
BACKGROUND Strontium ranelate is indicated for the treatment of postmenopausal osteoporosis. An association between strontium ranelate and venous thromboembolism (VTE) was identified in an analysis of phase III clinical trials. OBJECTIVE To estimate the incidence of VTE in patients within the strontium ranelate (Protelos(R)) Prescription-Event Monitoring (PEM) study cohort during the first 12 months after starting treatment. METHODS Patients in this analysis were identified from dispensed prescriptions that had been issued by general practitioners (GPs) in England for strontium ranelate between October 2004 and January 2008. For each individual patient, a Green Form questionnaire was sent to their GP 12 months after the date of the first prescription issued for strontium ranelate, requesting information about the patient including start and stop dates of treatment (if stopped), age, sex, indication, any history of VTE events, reasons for stopping and whether the patient had any events since starting the drug. VTE was defined as reports of deep vein thrombosis (DVT) or pulmonary embolism (PE). The crude incidence of VTE was calculated for events that occurred during the first 12 months after starting treatment (plus 30 days after stopping), with 95% Poisson exact CIs for the whole cohort, and subsets defined by age and past history of VTE. RESULTS The final analysis cohort consisted of 10 782 patients. Where specified, mean age was 73.3 years (SD 11.45) [n = 10 696]; 9833 (91.3%) were female and 934 (8.7%) were male. Where the history of VTE was specified, 233 patients (2.6%) had a history of VTE prior to starting. In the first 12-month period, there were 48 incident reports of VTE (DVT or PE) during treatment (or within 30 days of stopping) in the cohort, with 7696.89 years of exposure, giving a crude incidence rate of VTE of 6.24 cases (95% CI 4.60, 8.27) per 1000 patient-years exposed. CONCLUSIONS This analysis has provided an estimate of the incidence of VTE in patients treated with strontium ranelate in the general practice setting. The rate is similar to estimates in populations of similar age and corresponds to the incidence found in patients from phase III clinical studies and observational cohort studies of strontium ranelate on this topic. The crude annual incidence rate of VTE in the PEM cohort is higher than the background annual incidence rate found in the UK population, but is similar to estimates in populations of similar age and populations receiving treatment for postmenopausal osteoporosis. Also, we acknowledge the potential for underestimating the incidence in this population. Nevertheless, this analysis contributes to the ongoing postmarketing safety assessment of this product.
Collapse
|
42
|
Adare A, Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Al-Bataineh H, Alexander J, Aoki K, Aphecetche L, Aramaki Y, Asai J, Atomssa ET, Averbeck R, Awes TC, Azmoun B, Babintsev V, Bai M, Baksay G, Baksay L, Baldisseri A, Barish KN, Barnes PD, Bassalleck B, Basye AT, Bathe S, Batsouli S, Baublis V, Baumann C, Bazilevsky A, Belikov S, Belmont R, Bennett R, Berdnikov A, Berdnikov Y, Bickley AA, Boissevain JG, Bok JS, Borel H, Boyle K, Brooks ML, Buesching H, Bumazhnov V, Bunce G, Butsyk S, Camacho CM, Campbell S, Chang BS, Chang WC, Charvet JL, Chen CH, Chernichenko S, Chi CY, Chiu M, Choi IJ, Choudhury RK, Christiansen P, Chujo T, Chung P, Churyn A, Chvala O, Cianciolo V, Citron Z, Cole BA, Connors M, Constantin P, Csanád M, Csörgo T, Dahms T, Dairaku S, Danchev I, Das K, Datta A, David G, Denisov A, d'Enterria D, Deshpande A, Desmond EJ, Dietzsch O, Dion A, Donadelli M, Drapier O, Drees A, Drees KA, Dubey AK, Durham JM, Durum A, Dutta D, Dzhordzhadze V, Edwards S, Efremenko YV, Ellinghaus F, Engelmore T, Enokizono A, En'yo H, Esumi S, Eyser KO, Fadem B, Fields DE, Finger M, Finger M, Fleuret F, Fokin SL, Fraenkel Z, Frantz JE, Franz A, Frawley AD, Fujiwara K, Fukao Y, Fusayasu T, Garishvili I, Glenn A, Gong H, Gonin M, Gosset J, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grosse Perdekamp M, Gunji T, Gustafsson HA, Hadj Henni A, Haggerty JS, Hahn KI, Hamagaki H, Hamblen J, Hanks J, Han R, Hartouni EP, Haruna K, Haslum E, Hayano R, Heffner M, Hegyi S, Hemmick TK, Hester T, He X, Hill JC, Hohlmann M, Holzmann W, Homma K, Hong B, Horaguchi T, Hornback D, Huang S, Ichihara T, Ichimiya R, Ide J, Iinuma H, Ikeda Y, Imai K, Imrek J, Inaba M, Isenhower D, Ishihara M, Isobe T, Issah M, Isupov A, Ivanischev D, Jacak BV, Jia J, Jin J, Johnson BM, Joo KS, Jouan D, Jumper DS, Kajihara F, Kametani S, Kamihara N, Kamin J, Kang JH, Kapustinsky J, Kawall D, Kawashima M, Kazantsev AV, Kempel T, Khanzadeev A, Kijima KM, Kikuchi J, Kim BI, Kim DH, Kim DJ, Kim EJ, Kim E, Kim SH, Kim YJ, Kinney E, Kiriluk K, Kiss A, Kistenev E, Klay J, Klein-Boesing C, Kochenda L, Komkov B, Konno M, Koster J, Kotchetkov D, Kozlov A, Král A, Kravitz A, Kunde GJ, Kurita K, Kurosawa M, Kweon MJ, Kwon Y, Kyle GS, Lacey R, Lai YS, Lajoie JG, Layton D, Lebedev A, Lee DM, Lee J, Lee KB, Lee K, Lee KS, Lee T, Leitch MJ, Leite MAL, Leitner E, Lenzi B, Liebing P, Linden Levy LA, Liska T, Litvinenko A, Liu H, Liu MX, Li X, Love B, Luechtenborg R, Lynch D, Maguire CF, Makdisi YI, Malakhov A, Malik MD, Manko VI, Mannel E, Mao Y, Masek L, Masui H, Matathias F, McCumber M, McGaughey PL, Means N, Meredith B, Miake Y, Mignerey AC, Mikes P, Miki K, Milov A, Mishra M, Mitchell JT, Mohanty AK, Morino Y, Morreale A, Morrison DP, Moukhanova TV, Mukhopadhyay D, Murata J, Nagamiya S, Nagle JL, Naglis M, Nagy MI, Nakagawa I, Nakamiya Y, Nakamura T, Nakano K, Newby J, Nguyen M, Niita T, Nouicer R, Nyanin AS, O'Brien E, Oda SX, Ogilvie CA, Okada K, Oka M, Onuki Y, Oskarsson A, Ouchida M, Ozawa K, Pak R, Palounek APT, Pantuev V, Papavassiliou V, Park IH, Park J, Park SK, Park WJ, Pate SF, Pei H, Peng JC, Pereira H, Peresedov V, Peressounko DY, Pinkenburg C, Pisani RP, Proissl M, Purschke ML, Purwar AK, Qu H, Rak J, Rakotozafindrabe A, Ravinovich I, Read KF, Rembeczki S, Reygers K, Riabov V, Riabov Y, Richardson E, Roach D, Roche G, Rolnick SD, Rosati M, Rosen CA, Rosendahl SSE, Rosnet P, Rukoyatkin P, Ruzicka P, Rykov VL, Sahlmueller B, Saito N, Sakaguchi T, Sakai S, Sakashita K, Samsonov V, Sano S, Sato T, Sawada S, Sedgwick K, Seele J, Seidl R, Semenov AY, Semenov V, Seto R, Sharma D, Shein I, Shibata TA, Shigaki K, Shimomura M, Shoji K, Shukla P, Sickles A, Silva CL, Silvermyr D, Silvestre C, Sim KS, Singh BK, Singh CP, Singh V, Slunecka M, Soldatov A, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Sparks NA, Staley F, Stankus PW, Stenlund E, Stepanov M, Ster A, Stoll SP, Sugitate T, Suire C, Sukhanov A, Sziklai J, Takagui EM, Taketani A, Tanabe R, Tanaka Y, Tanida K, Tannenbaum MJ, Tarafdar S, Taranenko A, Tarján P, Themann H, Thomas TL, Togawa M, Toia A, Tomásek L, Tomita Y, Torii H, Towell RS, Tram VN, Tserruya I, Tsuchimoto Y, Vale C, Valle H, van Hecke HW, Vazquez-Zambrano E, Veicht A, Velkovska J, Vértesi R, Vinogradov AA, Virius M, Vrba V, Vznuzdaev E, Wang XR, Watanabe D, Watanabe K, Watanabe Y, Wei F, Wei R, Wessels J, White SN, Winter D, Wood JP, Woody CL, Wright RM, Wysocki M, Xie W, Yamaguchi YL, Yamaura K, Yang R, Yanovich A, Ying J, Yokkaichi S, Young GR, Younus I, You Z, Yushmanov IE, Zajc WA, Zaudtke O, Zhang C, Zhou S, Zolin L. Transition in yield and azimuthal shape modification in dihadron correlations in relativistic heavy ion collisions. PHYSICAL REVIEW LETTERS 2010; 104:252301. [PMID: 20867367 DOI: 10.1103/physrevlett.104.252301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/05/2010] [Indexed: 05/29/2023]
Abstract
Hard-scattered parton probes produced in collisions of large nuclei indicate large partonic energy loss, possibly with collective produced-medium response to the lost energy. We present measurements of π^{0} trigger particles at transverse momenta p{T}{t}=4-12 GeV/c and associated charged hadrons (p{T}{a}=0.5-7 GeV/c) vs relative azimuthal angle Δϕ in Au+Au and p+p collisions at sqrt[s{NN}]=200 GeV. The Au+Au distribution at low p{T}{a}, whose shape has been interpreted as a medium effect, is modified for p{T}{t}<7 GeV/c. At higher p{T}{t}, the data are consistent with unmodified or very weakly modified shapes, even for the lowest measured p{T}{a}, which quantitatively challenges some medium response models. The associated yield of hadrons opposing the trigger particle in Au+Au relative to p+p (I{AA}) is suppressed at high p{T} (I{AA}≈0.35-0.5), but less than for inclusive suppression (R{AA}≈0.2).
Collapse
|
43
|
Osborne V, Hazell L, Layton D, Shakir SA. Drug Utilization of Intrinsa® (Testosterone Patch) in England. Drug Saf 2010; 33:213-21. [DOI: 10.2165/11533720-000000000-00000] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
44
|
Buggy Y, Layton D, Fogg C, Shakir SA. Safety profile of oxcarbazepine: Results from a prescription-event monitoring study. Epilepsia 2010; 51:818-29. [DOI: 10.1111/j.1528-1167.2009.02489.x] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
|
45
|
Adare A, Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Al-Bataineh H, Alexander J, Aoki K, Aphecetche L, Armendariz R, Aronson SH, Asai J, Aschenauer EC, Atomssa ET, Averbeck R, Awes TC, Azmoun B, Babintsev V, Bai M, Baksay G, Baksay L, Baldisseri A, Barish KN, Barnes PD, Bassalleck B, Basye AT, Bathe S, Batsouli S, Baublis V, Baumann C, Bazilevsky A, Belikov S, Bennett R, Berdnikov A, Berdnikov Y, Bickley AA, Boissevain JG, Borel H, Boyle K, Brooks ML, Buesching H, Bumazhnov V, Bunce G, Butsyk S, Camacho CM, Campbell S, Chang BS, Chang WC, Charvet JL, Chernichenko S, Chiba J, Chi CY, Chiu M, Choi IJ, Choudhury RK, Chujo T, Chung P, Churyn A, Cianciolo V, Citron Z, Cleven CR, Cole BA, Comets MP, Constantin P, Csanád M, Csörgő T, Dahms T, Dairaku S, Das K, David G, Deaton MB, Dehmelt K, Delagrange H, Denisov A, d’Enterria D, Deshpande A, Desmond EJ, Dietzsch O, Dion A, Donadelli M, Drapier O, Drees A, Drees KA, Dubey AK, Durum A, Dutta D, Dzhordzhadze V, Efremenko YV, Egdemir J, Ellinghaus F, Emam WS, Engelmore T, Enokizono A, En’yo H, Esumi S, Eyser KO, Fadem B, Fields DE, Finger M, Finger M, Fleuret F, Fokin SL, Fraenkel Z, Frantz JE, Franz A, Frawley AD, Fujiwara K, Fukao Y, Fusayasu T, Gadrat S, Garishvili I, Glenn A, Gong H, Gonin M, Gosset J, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grosse Perdekamp M, Gunji T, Gustafsson HÅ, Hachiya T, Hadj Henni A, Haegemann C, Haggerty JS, Hamagaki H, Han R, Harada H, Hartouni EP, Haruna K, Haslum E, Hayano R, Heffner M, Hemmick TK, Hester T, He X, Hiejima H, Hill JC, Hobbs R, Hohlmann M, Holzmann W, Homma K, Hong B, Horaguchi T, Hornback D, Huang S, Ichihara T, Ichimiya R, Iinuma H, Ikeda Y, Imai K, Imrek J, Inaba M, Inoue Y, Isenhower D, Isenhower L, Ishihara M, Isobe T, Issah M, Isupov A, Ivanischev D, Jacak BV, Jia J, Jin J, Jinnouchi O, Johnson BM, Joo KS, Jouan D, Kajihara F, Kametani S, Kamihara N, Kamin J, Kaneta M, Kang JH, Kanou H, Kapustinsky J, Kawall D, Kazantsev AV, Kempel T, Khanzadeev A, Kijima KM, Kikuchi J, Kim BI, Kim DH, Kim DJ, Kim E, Kim SH, Kinney E, Kiriluk K, Kiss Á, Kistenev E, Kiyomichi A, Klay J, Klein-Boesing C, Kochenda L, Kochetkov V, Komkov B, Konno M, Koster J, Kotchetkov D, Kozlov A, Král A, Kravitz A, Kubart J, Kunde GJ, Kurihara N, Kurita K, Kurosawa M, Kweon MJ, Kwon Y, Kyle GS, Lacey R, Lai YS, Lai YS, Lajoie JG, Layton D, Lebedev A, Lee DM, Lee KB, Lee MK, Lee T, Leitch MJ, Leite MAL, Lenzi B, Liebing P, Liška T, Litvinenko A, Liu H, Liu MX, Li X, Love B, Lynch D, Maguire CF, Makdisi YI, Malakhov A, Malik MD, Manko VI, Mannel E, Mao Y, Mašek L, Masui H, Matathias F, McCumber M, McGaughey PL, Means N, Meredith B, Miake Y, Mikeš P, Miki K, Miller TE, Milov A, Mioduszewski S, Mishra M, Mitchell JT, Mitrovski M, Mohanty AK, Morino Y, Morreale A, Morrison DP, Moukhanova TV, Mukhopadhyay D, Murata J, Nagamiya S, Nagata Y, Nagle JL, Naglis M, Nagy MI, Nakagawa I, Nakamiya Y, Nakamura T, Nakano K, Newby J, Nguyen M, Niita T, Norman BE, Nouicer R, Nyanin AS, O’Brien E, Oda SX, Ogilvie CA, Ohnishi H, Okada K, Oka M, Omiwade OO, Onuki Y, Oskarsson A, Ouchida M, Ozawa K, Pak R, Pal D, Palounek APT, Pantuev V, Papavassiliou V, Park J, Park WJ, Pate SF, Pei H, Peng JC, Pereira H, Peresedov V, Peressounko DY, Pinkenburg C, Purschke ML, Purwar AK, Qu H, Rak J, Rakotozafindrabe A, Ravinovich I, Read KF, Rembeczki S, Reuter M, Reygers K, Riabov V, Riabov Y, Roach D, Roche G, Rolnick SD, Romana A, Rosati M, Rosendahl SSE, Rosnet P, Rukoyatkin P, Ružička P, Rykov VL, Sahlmueller B, Saito N, Sakaguchi T, Sakai S, Sakashita K, Sakata H, Samsonov V, Sato S, Sato T, Sawada S, Sedgwick K, Seele J, Seidl R, Semenov AY, Semenov V, Seto R, Sharma D, Shein I, Shevel A, Shibata TA, Shigaki K, Shimomura M, Shoji K, Shukla P, Sickles A, Silva CL, Silvermyr D, Silvestre C, Sim KS, Singh BK, Singh CP, Singh V, Skutnik S, Slunečka M, Soldatov A, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Staley F, Stankus PW, Stenlund E, Stepanov M, Ster A, Stoll SP, Sugitate T, Suire C, Sukhanov A, Sziklai J, Tabaru T, Takagi S, Takagui EM, Taketani A, Tanabe R, Tanaka Y, Tanida K, Tannenbaum MJ, Taranenko A, Tarján P, Themann H, Thomas TL, Togawa M, Toia A, Tojo J, Tomášek L, Tomita Y, Torii H, Towell RS, Tram VN, Tserruya I, Tsuchimoto Y, Vale C, Valle H, van Hecke HW, Veicht A, Velkovska J, Vértesi R, Vinogradov AA, Virius M, Vrba V, Vznuzdaev E, Wagner M, Walker D, Wang XR, Watanabe Y, Wei F, Wessels J, White SN, Winter D, Woody CL, Wysocki M, Xie W, Yamaguchi YL, Yamaura K, Yang R, Yanovich A, Yasin Z, Ying J, Yokkaichi S, Young GR, Younus I, Yushmanov IE, Zajc WA, Zaudtke O, Zhang C, Zhou S, Zimányi J, Zolin L. Double-helicity dependence of jet properties from dihadrons in longitudinally polarizedp+pcollisions ats=200 GeV. Int J Clin Exp Med 2010. [DOI: 10.1103/physrevd.81.012002] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
46
|
Adare A, Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Al-Bataineh H, Alexander J, Aoki K, Aphecetche L, Armendariz R, Aronson SH, Asai J, Atomssa ET, Averbeck R, Awes TC, Azmoun B, Babintsev V, Bai M, Baksay G, Baksay L, Baldisseri A, Barish KN, Barnes PD, Bassalleck B, Basye AT, Bathe S, Batsouli S, Baublis V, Baumann C, Bazilevsky A, Belikov S, Bennett R, Berdnikov A, Berdnikov Y, Bickley AA, Boissevain JG, Borel H, Boyle K, Brooks ML, Buesching H, Bumazhnov V, Bunce G, Butsyk S, Camacho CM, Campbell S, Chang BS, Chang WC, Charvet JL, Chernichenko S, Chiba J, Chi CY, Chiu M, Choi IJ, Choudhury RK, Chujo T, Chung P, Churyn A, Cianciolo V, Citron Z, Cleven CR, Cole BA, Comets MP, Constantin P, Csanád M, Csörgo T, Dahms T, Dairaku S, Das K, David G, Deaton MB, Dehmelt K, Delagrange H, Denisov A, d'Enterria D, Deshpande A, Desmond EJ, Dietzsch O, Dion A, Donadelli M, Drapier O, Drees A, Drees KA, Dubey AK, Durum A, Dutta D, Dzhordzhadze V, Efremenko YV, Egdemir J, Ellinghaus F, Emam WS, Engelmore T, Enokizono A, En'yo H, Esumi S, Eyser KO, Fadem B, Fields DE, Finger M, Finger M, Fleuret F, Fokin SL, Fraenkel Z, Frantz JE, Franz A, Frawley AD, Fujiwara K, Fukao Y, Fusayasu T, Gadrat S, Garishvili I, Glenn A, Gong H, Gonin M, Gosset J, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Perdekamp MG, Gunji T, Gustafsson HA, Hachiya T, Henni AH, Haegemann C, Haggerty JS, Hamagaki H, Han R, Harada H, Hartouni EP, Haruna K, Haslum E, Hayano R, Heffner M, Hemmick TK, Hester T, He X, Hiejima H, Hill JC, Hobbs R, Hohlmann M, Holzmann W, Homma K, Hong B, Horaguchi T, Hornback D, Huang S, Ichihara T, Ichimiya R, Ikeda Y, Imai K, Imrek J, Inaba M, Inoue Y, Isenhower D, Isenhower L, Ishihara M, Isobe T, Issah M, Isupov A, Ivanischev D, Jacak BV, Jia J, Jin J, Jinnouchi O, Johnson BM, Joo KS, Jouan D, Kajihara F, Kametani S, Kamihara N, Kamin J, Kaneta M, Kang JH, Kanou H, Kapustinsky J, Kawall D, Kazantsev AV, Kempel T, Khanzadeev A, Kijima KM, Kikuchi J, Kim BI, Kim DH, Kim DJ, Kim E, Kim SH, Kinney E, Kiriluk K, Kiss A, Kistenev E, Kiyomichi A, Klay J, Klein-Boesing C, Kochenda L, Kochetkov V, Komkov B, Konno M, Koster J, Kotchetkov D, Kozlov A, Král A, Kravitz A, Kubart J, Kunde GJ, Kurihara N, Kurita K, Kurosawa M, Kweon MJ, Kwon Y, Kyle GS, Lacey R, Lai YS, Lai YS, Lajoie JG, Layton D, Lebedev A, Lee DM, Lee KB, Lee MK, Lee T, Leitch MJ, Leite MAL, Lenzi B, Liebing P, Liska T, Litvinenko A, Liu H, Liu MX, Li X, Love B, Lynch D, Maguire CF, Makdisi YI, Malakhov A, Malik MD, Manko VI, Mannel E, Mao Y, Masek L, Masui H, Matathias F, McCumber M, McGaughey PL, Means N, Meredith B, Miake Y, Mikes P, Miki K, Miller TE, Milov A, Mioduszewski S, Mishra M, Mitchell JT, Mitrovski M, Mohanty AK, Morino Y, Morreale A, Morrison DP, Moukhanova TV, Mukhopadhyay D, Murata J, Nagamiya S, Nagata Y, Nagle JL, Naglis M, Nagy MI, Nakagawa I, Nakamiya Y, Nakamura T, Nakano K, Newby J, Nguyen M, Niita T, Norman BE, Nouicer R, Nyanin AS, O'Brien E, Oda SX, Ogilvie CA, Ohnishi H, Okada H, Okada K, Oka M, Omiwade OO, Onuki Y, Oskarsson A, Ouchida M, Ozawa K, Pak R, Pal D, Palounek APT, Pantuev V, Papavassiliou V, Park J, Park WJ, Pate SF, Pei H, Peng JC, Pereira H, Peresedov V, Peressounko DY, Pinkenburg C, Purschke ML, Purwar AK, Qu H, Rak J, Rakotozafindrabe A, Ravinovich I, Read KF, Rembeczki S, Reuter M, Reygers K, Riabov V, Riabov Y, Roach D, Roche G, Rolnick SD, Romana A, Rosati M, Rosendahl SSE, Rosnet P, Rukoyatkin P, Ruzicka P, Rykov VL, Sahlmueller B, Saito N, Sakaguchi T, Sakai S, Sakashita K, Sakata H, Samsonov V, Sato S, Sato T, Sawada S, Sedgwick K, Seele J, Seidl R, Semenov AY, Semenov V, Seto R, Sharma D, Shein I, Shevel A, Shibata TA, Shigaki K, Shimomura M, Shoji K, Shukla P, Sickles A, Silva CL, Silvermyr D, Silvestre C, Sim KS, Singh BK, Singh CP, Singh V, Skutnik S, Slunecka M, Soldatov A, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Staley F, Stankus PW, Stenlund E, Stepanov M, Ster A, Stoll SP, Sugitate T, Suire C, Sukhanov A, Sziklai J, Tabaru T, Takagi S, Takagui EM, Taketani A, Tanabe R, Tanaka Y, Tanida K, Tannenbaum MJ, Taranenko A, Tarján P, Themann H, Thomas TL, Togawa M, Toia A, Tojo J, Tomásek L, Tomita Y, Torii H, Towell RS, Tram VN, Tserruya I, Tsuchimoto Y, Vale C, Valle H, van Hecke HW, Veicht A, Velkovska J, Vertesi R, Vinogradov AA, Virius M, Vrba V, Vznuzdaev E, Wagner M, Walker D, Wang XR, Watanabe Y, Wei F, Wessels J, White SN, Winter D, Woody CL, Wysocki M, Xie W, Yamaguchi YL, Yamaura K, Yang R, Yanovich A, Yasin Z, Ying J, Yokkaichi S, Young GR, Younus I, Yushmanov IE, Zajc WA, Zaudtke O, Zhang C, Zhou S, Zimányi J, Zolin L. Measurement of bottom versus charm as a function of transverse momentum with electron-hadron correlations in p + p collisions at square root of s = 200 GeV. PHYSICAL REVIEW LETTERS 2009; 103:082002. [PMID: 19792719 DOI: 10.1103/physrevlett.103.082002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/29/2009] [Indexed: 05/28/2023]
Abstract
The momentum distribution of electrons from semileptonic decays of charm and bottom quarks for midrapidity |y|<0.35 in p+p collisions at square root of s=200 GeV is measured by the PHENIX experiment at the Relativistic Heavy Ion Collider over the transverse momentum range 2<pT<7 GeV/c. The ratio of the yield of electrons from bottom to that from charm is presented. The ratio is determined using partial D/D-->e(+/-)K(-/+)X (K unidentified) reconstruction. It is found that the yield of electrons from bottom becomes significant above 4 GeV/c in pT. A fixed-order-plus-next-to-leading-log perturbative quantum chromodynamics calculation agrees with the data within the theoretical and experimental uncertainties. The extracted total bottom production cross section at this energy is sigma(bb)=3.2(-1.1)(+1.2)(stat)(-1.3)(+1.4)(syst)mub.
Collapse
|
47
|
Adare A, Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Al-Bataineh H, Alexander J, Aoki K, Aphecetche L, Asai J, Atomssa ET, Averbeck R, Awes TC, Azmoun B, Babintsev V, Bai M, Baksay G, Baksay L, Baldisseri A, Barish KN, Barnes PD, Bassalleck B, Basye AT, Bathe S, Batsouli S, Baublis V, Baumann C, Bazilevsky A, Belikov S, Bennett R, Berdnikov A, Berdnikov Y, Bickley AA, Boissevain JG, Borel H, Boyle K, Brooks ML, Buesching H, Bumazhnov V, Bunce G, Butsyk S, Camacho CM, Campbell S, Chand P, Chang BS, Chang WC, Charvet JL, Chernichenko S, Chi CY, Chiu M, Choi IJ, Choudhury RK, Chujo T, Chung P, Churyn A, Cianciolo V, Citron Z, Cole BA, Constantin P, Csanád M, Csörgo T, Dahms T, Dairaku S, Das K, David G, Denisov A, d'Enterria D, Deshpande A, Desmond EJ, Dietzsch O, Dion A, Donadelli M, Drapier O, Drees A, Drees KA, Dubey AK, Durum A, Dutta D, Dzhordzhadze V, Efremenko YV, Egdemir J, Ellinghaus F, Engelmore T, Enokizono A, En'yo H, Esumi S, Eyser KO, Fadem B, Fields DE, Finger M, Finger M, Fleuret F, Fokin SL, Fraenkel Z, Frantz JE, Franz A, Frawley AD, Fujiwara K, Fukao Y, Fusayasu T, Garishvili I, Glenn A, Gong H, Gonin M, Gosset J, Goto Y, de Cassagnac RG, Grau N, Greene SV, Perdekamp MG, Gunji T, Gustafsson HA, Henni AH, Haggerty JS, Hamagaki H, Han R, Hartouni EP, Haruna K, Haslum E, Hayano R, Heffner M, Hemmick TK, Hester T, He X, Hill JC, Hohlmann M, Holzmann W, Homma K, Hong B, Horaguchi T, Hornback D, Huang S, Ichihara T, Ichimiya R, Ikeda Y, Imai K, Imrek J, Inaba M, Isenhower D, Ishihara M, Isobe T, Issah M, Isupov A, Ivanischev D, Jacak BV, Jia J, Jin J, Johnson BM, Joo KS, Jouan D, Kajihara F, Kametani S, Kamihara N, Kamin J, Kang JH, Kapustinsky J, Kawall D, Kazantsev AV, Kempel T, Khanzadeev A, Kijima KM, Kikuchi J, Kim BI, Kim DH, Kim DJ, Kim E, Kim SH, Kinney E, Kiriluk K, Kiss A, Kistenev E, Klay J, Klein-Boesing C, Kochenda L, Kochetkov V, Komkov B, Konno M, Koster J, Kozlov A, Král A, Kravitz A, Kunde GJ, Kurita K, Kurosawa M, Kweon MJ, Kwon Y, Kyle GS, Lacey R, Lai YS, Lajoie JG, Layton D, Lebedev A, Lee DM, Lee KB, Lee T, Leitch MJ, Leite MAL, Lenzi B, Liebing P, Liska T, Litvinenko A, Liu H, Liu MX, Li X, Love B, Lynch D, Maguire CF, Makdisi YI, Malakhov A, Malik MD, Manko VI, Mannel E, Mao Y, Masek L, Masui H, Matathias F, McCumber M, McGaughey PL, Means N, Meredith B, Miake Y, Mikes P, Miki K, Milov A, Mishra M, Mitchell JT, Mohanty AK, Morino Y, Morreale A, Morrison DP, Moukhanova TV, Mukhopadhyay D, Murata J, Nagamiya S, Nagle JL, Naglis M, Nagy MI, Nakagawa I, Nakamiya Y, Nakamura T, Nakano K, Newby J, Nguyen M, Niita T, Nouicer R, Nyanin AS, O'Brien E, Oda SX, Ogilvie CA, Okada H, Okada K, Oka M, Onuki Y, Oskarsson A, Ouchida M, Ozawa K, Pak R, Palounek APT, Pantuev V, Papavassiliou V, Park J, Park WJ, Pate SF, Pei H, Peng JC, Pereira H, Peresedov V, Peressounko DY, Pinkenburg C, Purschke ML, Purwar AK, Qu H, Rak J, Rakotozafindrabe A, Ravinovich I, Read KF, Rembeczki S, Reuter M, Reygers K, Riabov V, Riabov Y, Roach D, Roche G, Rolnick SD, Rosati M, Rosendahl SSE, Rosnet P, Rukoyatkin P, Ruzicka P, Rykov VL, Sahlmueller B, Saito N, Sakaguchi T, Sakai S, Sakashita K, Samsonov V, Sato T, Sawada S, Sedgwick K, Seele J, Seidl R, Semenov AY, Semenov V, Seto R, Sharma D, Shein I, Shibata TA, Shigaki K, Shimomura M, Shoji K, Shukla P, Sickles A, Silva CL, Silvermyr D, Silvestre C, Sim KS, Singh BK, Singh CP, Singh V, Slunecka M, Soldatov A, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Staley F, Stankus PW, Stenlund E, Stepanov M, Ster A, Stoll SP, Sugitate T, Suire C, Sukhanov A, Sziklai J, Takagui EM, Taketani A, Tanabe R, Tanaka Y, Taneja S, Tanida K, Tannenbaum MJ, Taranenko A, Tarján P, Themann H, Thomas TL, Togawa M, Toia A, Tomásek L, Tomita Y, Torii H, Towell RS, Tram VN, Tserruya I, Tsuchimoto Y, Vale C, Valle H, van Hecke HW, Veicht A, Velkovska J, Vertesi R, Vinogradov AA, Virius M, Vrba V, Vznuzdaev E, Walker D, Wang XR, Watanabe Y, Wei F, Wessels J, White SN, Williamson S, Winter D, Woody CL, Wysocki M, Xie W, Yamaguchi YL, Yamaura K, Yang R, Yanovich A, Ying J, Yokkaichi S, Young GR, Younus I, Yushmanov IE, Zajc WA, Zaudtke O, Zhang C, Zhou S, Zolin L. Gluon-spin contribution to the proton spin from the double-helicity asymmetry in inclusive pi0 production in polarized p+p collisions at [sqrt]s=200 GeV. PHYSICAL REVIEW LETTERS 2009; 103:012003. [PMID: 19659137 DOI: 10.1103/physrevlett.103.012003] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/06/2008] [Indexed: 05/28/2023]
Abstract
The double helicity asymmetry in neutral pion production for pT=1 to 12 GeV/c was measured with the PHENIX experiment to access the gluon-spin contribution, DeltaG, to the proton spin. Measured asymmetries are consistent with zero, and at a theory scale of micro2=4 GeV2 a next to leading order QCD analysis gives DeltaG[0.02,0.3]=0.2, with a constraint of -0.7<DeltaG[0.02,0.3]<0.5 at Deltachi2=9 (approximately 3sigma) for the sampled gluon momentum fraction (x) range, 0.02 to 0.3. The results are obtained using predictions for the measured asymmetries generated from four representative fits to polarized deep inelastic scattering data. We also consider the dependence of the DeltaG constraint on the choice of the theoretical scale, a dominant uncertainty in these predictions.
Collapse
|
48
|
Layton D, Wilton L, Shakir SA. Examining the Tolerability of the Non-Sedating Antihistamine Desloratadine. Drug Saf 2009; 32:169-79. [DOI: 10.2165/00002018-200932020-00009] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
49
|
Adare A, Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Al-Bataineh H, Alexander J, Aoki K, Aphecetche L, Armendariz R, Aronson SH, Asai J, Atomssa ET, Averbeck R, Awes TC, Azmoun B, Babintsev V, Bai M, Baksay G, Baksay L, Baldisseri A, Barish KN, Barnes PD, Bassalleck B, Basye AT, Bathe S, Batsouli S, Baublis V, Baumann C, Bazilevsky A, Belikov S, Bennett R, Berdnikov A, Berdnikov Y, Bickley AA, Boissevain JG, Borel H, Boyle K, Brooks ML, Buesching H, Bumazhnov V, Bunce G, Butsyk S, Camacho CM, Campbell S, Chang BS, Chang WC, Charvet JL, Chernichenko S, Chiba J, Chi CY, Chiu M, Choi IJ, Choudhury RK, Chujo T, Chung P, Churyn A, Cianciolo V, Citron Z, Cleven CR, Cole BA, Comets MP, Constantin P, Csanád M, Csörgo T, Dahms T, Dairaku S, Das K, David G, Deaton MB, Dehmelt K, Delagrange H, Denisov A, d'Enterria D, Deshpande A, Desmond EJ, Dietzsch O, Dion A, Donadelli M, Drapier O, Drees A, Drees KA, Dubey AK, Durum A, Dutta D, Dzhordzhadze V, Efremenko YV, Egdemir J, Ellinghaus F, Emam WS, Engelmore T, Enokizono A, En'yo H, Esumi S, Eyser KO, Fadem B, Fields DE, Finger M, Finger M, Fleuret F, Fokin SL, Fraenkel Z, Frantz JE, Franz A, Frawley AD, Fujiwara K, Fukao Y, Fusayasu T, Gadrat S, Garishvili I, Glenn A, Gong H, Gonin M, Gosset J, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grosse Perdekamp M, Gunji T, Gustafsson HA, Hachiya T, Hadj Henni A, Haegemann C, Haggerty JS, Hamagaki H, Han R, Harada H, Hartouni EP, Haruna K, Haslum E, Hayano R, Heffner M, Hemmick TK, Hester T, He X, Hiejima H, Hill JC, Hobbs R, Hohlmann M, Holzmann W, Homma K, Hong B, Horaguchi T, Hornback D, Huang S, Ichihara T, Ichimiya R, Ikeda Y, Imai K, Imrek J, Inaba M, Inoue Y, Isenhower D, Isenhower L, Ishihara M, Isobe T, Issah M, Isupov A, Ivanischev D, Jacak BV, Jia J, Jin J, Jinnouchi O, Johnson BM, Joo KS, Jouan D, Kajihara F, Kametani S, Kamihara N, Kamin J, Kaneta M, Kang JH, Kanou H, Kapustinsky J, Kawall D, Kazantsev AV, Kempel T, Khanzadeev A, Kijima KM, Kikuchi J, Kim BI, Kim DH, Kim DJ, Kim E, Kim SH, Kinney E, Kiriluk K, Kiss A, Kistenev E, Kiyomichi A, Klay J, Klein-Boesing C, Kochenda L, Kochetkov V, Komkov B, Konno M, Koster J, Kotchetkov D, Kozlov A, Král A, Kravitz A, Kubart J, Kunde GJ, Kurihara N, Kurita K, Kurosawa M, Kweon MJ, Kwon Y, Kyle GS, Lacey R, Lai YS, Lai YS, Lajoie JG, Layton D, Lebedev A, Lee DM, Lee KB, Lee MK, Lee T, Leitch MJ, Leite MAL, Lenzi B, Liebing P, Liska T, Litvinenko A, Liu H, Liu MX, Li X, Love B, Lynch D, Maguire CF, Makdisi YI, Malakhov A, Malik MD, Manko VI, Mannel E, Mao Y, Masek L, Masui H, Matathias F, McCumber M, McGaughey PL, Means N, Meredith B, Miake Y, Mikes P, Miki K, Miller TE, Milov A, Mioduszewski S, Mishra M, Mitchell JT, Mitrovski M, Mohanty AK, Morino Y, Morreale A, Morrison DP, Moukhanova TV, Mukhopadhyay D, Murata J, Nagamiya S, Nagata Y, Nagle JL, Naglis M, Nagy MI, Nakagawa I, Nakamiya Y, Nakamura T, Nakano K, Newby J, Nguyen M, Niita T, Norman BE, Nouicer R, Nyanin AS, O'Brien E, Oda SX, Ogilvie CA, Ohnishi H, Okada H, Okada K, Oka M, Omiwade OO, Onuki Y, Oskarsson A, Ouchida M, Ozawa K, Pak R, Pal D, Palounek APT, Pantuev V, Papavassiliou V, Park J, Park WJ, Pate SF, Pei H, Peng JC, Pereira H, Peresedov V, Peressounko DY, Pinkenburg C, Purschke ML, Purwar AK, Qu H, Rak J, Rakotozafindrabe A, Ravinovich I, Read KF, Rembeczki S, Reuter M, Reygers K, Riabov V, Riabov Y, Roach D, Roche G, Rolnick SD, Romana A, Rosati M, Rosendahl SSE, Rosnet P, Rukoyatkin P, Ruzicka P, Rykov VL, Sahlmueller B, Saito N, Sakaguchi T, Sakai S, Sakashita K, Sakata H, Samsonov V, Sato S, Sato T, Sawada S, Sedgwick K, Seele J, Seidl R, Semenov AY, Semenov V, Seto R, Sharma D, Shein I, Shevel A, Shibata TA, Shigaki K, Shimomura M, Shoji K, Shukla P, Sickles A, Silva CL, Silvermyr D, Silvestre C, Sim KS, Singh BK, Singh CP, Singh V, Skutnik S, Slunecka M, Soldatov A, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Staley F, Stankus PW, Stenlund E, Stepanov M, Ster A, Stoll SP, Sugitate T, Suire C, Sukhanov A, Sziklai J, Tabaru T, Takagi S, Takagui EM, Taketani A, Tanabe R, Tanaka Y, Tanida K, Tannenbaum MJ, Taranenko A, Tarján P, Themann H, Thomas TL, Togawa M, Toia A, Tojo J, Tomásek L, Tomita Y, Torii H, Towell RS, Tram VN, Tserruya I, Tsuchimoto Y, Vale C, Valle H, vanHecke HW, Veicht A, Velkovska J, Vertesi R, Vinogradov AA, Virius M, Vrba V, Vznuzdaev E, Wagner M, Walker D, Wang XR, Watanabe Y, Wei F, Wessels J, White SN, Winter D, Woody CL, Wysocki M, Xie W, Yamaguchi YL, Yamaura K, Yang R, Yanovich A, Yasin Z, Ying J, Yokkaichi S, Young GR, Younus I, Yushmanov IE, Zajc WA, Zaudtke O, Zhang C, Zhou S, Zimányi J, Zolin L. Onset of pi(0) suppression studied in Cu+Cu collisions at sqrt S NN=22.4, 62.4, and 200 GeV. PHYSICAL REVIEW LETTERS 2008; 101:162301. [PMID: 18999660 DOI: 10.1103/physrevlett.101.162301] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/30/2008] [Indexed: 05/27/2023]
Abstract
Neutral pion transverse momentum (p(T)) spectra at midrapidity (|y| less than or approximately 0.35) were measured in Cu+Cu collisions at sqrt[s(NN)]=22.4, 62.4, and 200 GeV. Relative to pi_(0) yields in p+p collisions scaled by the number of inelastic nucleon-nucleon collisions (N(coll) the pi_(0) yields for p(T) more than or approximately 2 GeV/c in central Cu+Cu collisions are suppressed at 62.4 and 200 GeV whereas an enhancement is observed at 22.4 GeV. A comparison with a jet-quenching model suggests that final state parton energy loss dominates in central Cu+Cu collisions at 62.4 and 200 GeV, while the enhancement at 22.4 GeV is consistent with nuclear modifications in the initial state alone.
Collapse
|
50
|
Layton D, Souverein PC, Heerdink ER, Shakir SAW, Egberts AGC. Prescriber adoption of newly approved selective COX-2 inhibitors. Pharmacoepidemiol Drug Saf 2008; 17:1168-74. [PMID: 18821717 DOI: 10.1002/pds.1667] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
INTRODUCTION There is no consistent definition of prescribers who adopt new drug treatments early. This study examines if COX-2 inhibitors (coxibs) were prescribed by subsets of practitioners and describes GP adoption patterns of coxibs and existing NSAIDs over time. METHODS A population-based drug utilisation study using a Dutch medication claims database. Prescribers of patients (18+yrs) prescribed an NSAID January 1999-December 2003 were identified. Four NSAID categories were chosen reflecting selectivity (coxibs, preferential COX-2 inhibitors and non-selective (ns) NSAIDs (sub-categorised as first or second line treatment)). The characteristics of prescribers issuing>10 prescriptions examined were: Type (GP, Specialist, Other); GP NSAID prescribing preference ratio (nsNSAIDs/coxib first prescription); coxib (ratio<3); prescriber proportion responsible for 100%, 80% and 50% of initiations. Odds Ratios (95%CI) were calculated (first-line nsNSAIDs as reference). Plots of prescribing proportions by quarter year were examined. RESULTS NSAID cohorts comprised: first-line ns (N=38783); second-line ns (N=1459); COX-2 preferential (N=3107); coxib (N=4202) patients. For all four cohorts, GPs were the most common prescriber type (>67%); the most frequent prescribing preference was for first-line nsNSAIDs; 50% percentile prescribing proportions were low (<9%). GPs were equally as likely to prescribe coxibs as first-line nsNSAIDs [OR 1.0 (0.9, 1.1)]. Plots of 100% prescriber proportion for first-line nsNSAIDs and coxibs showed convergence; 50th percentile prescriber proportions plots were constant. CONCLUSIONS Small subsets of prescribers accounted for the majority of initiations regardless of NSAID type. Further studies are needed on such prescribers to inform healthcare policies and encourage participation in post-marketing safety studies.
Collapse
|